glp-1 cardiovascular outcomes trial august 2025 Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA Beyond obesity: Novo's SELECT re-defines

CXCL10 triggers early microglial activation in the cuprizone model

Yuan H, Perry CN, Huang C, Iwai-Kanai E, Carreira RS, Glembotski CC, and Gottlieb RA

Metabolic syndrome MetS refers to a constellation of metabolic disorders that include central obesity, dyslipidemia (raised triglycerides (TGs) and lowered high-density lipoprotein cholesterol), raised blood pressure, and raised fasting glucose, and can be diagnosed when any three of the above five components are present 11 (Table 1)

Batch Documentation Current batch status Batch 002 Testing In Progress Independent analytical testing is in progress Results will be posted once finalized Independent analytical testing is in progress

They suggested that a conformational change of these helices could open the gate and form a large ion channel inside the hydrophobic plasma membrane 55

Those who had a responsive genetic score were up to 82% more likely to achieve significant weight loss with a GLP-1 medication